FDA approves donanemab, Eli Lilly’s treatment for early Alzheimer’s disease ...Middle East

News channel - News
FDA approves donanemab, Eli Lilly’s treatment for early Alzheimer’s disease
By Jen Christensen, CNN (CNN) — The US Food and Drug Administration on Tuesday approved donanemab, a monoclonal antibody designed to slow the progression of early symptomatic Alzheimer’s disease. Donanemab, made by Indianapolis-based Eli Lilly, works by helping the body remove amyloid plaque buildup in the brain, a hallmark of Alzheimer’s disease. Lilly said it will be sold under the name Kisunla and would cost $695 per vial before insurance, what would amount to $12,522 for a six-month course or about $32,000 for a year. This is a developing story and will be updated. The-CNN-Wire™ & © 2024 Cable News Network, Inc., a Warner Bros. Discovery Company. All rights reserved. The post

Hence then, the article about fda approves donanemab eli lilly s treatment for early alzheimer s disease was published today ( ) and is available on News channel ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( FDA approves donanemab, Eli Lilly’s treatment for early Alzheimer’s disease )

Apple Storegoogle play

Last updated :

Also on site :

Most viewed in News


Latest News